Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Roche, Medicines Patent Pool sign voluntary license for generic Xofluza access in 129 low- and middle-income countries
Licensing deal, infectious disease, small molecule, manufacturing, equity access - Read more

Incyte, Edison Scientific partner to deploy Kosmos AI across drug discovery and R&D workflows
Research collaboration, AI/ML, drug discovery, R&D, oncology - Read more

Merck & Co., Exelixis ink Keytruda supply deal for phase 3 colorectal cancer MRD trial
Supply agreement, oncology, small molecule, antibody, co-development - Read more

Herantis Pharma, Indivi partner on digital biomarker integration for Parkinson's disease phase 2 trial
Research collaboration, neurological, digital health, diagnostics, small molecule - Read more

SERB Pharmaceuticals acquires European and MENA rights to Idefirix from Hansa Biopharma for €115M ($134M)
Acquisition, rare disease, transplantation, milestone payments, small molecule, commercialization - Read more

QIAGEN, NVIDIA collaborate on graph-based AI integration for drug discovery using BioNeMo platform
Research collaboration, AI/ML, drug discovery, bioinformatics, data analytics - Read more

Eton Pharmaceuticals, Knight Therapeutics partner on U.S. commercialization rights to rare disease drug IMPAVIDO
Licensing deal, rare disease, infectious disease, small molecule, commercialization - Read more

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

UCB's Bimzelx (bimekizumab) outperforms Skyrizi in Ph3 head-to-head trial for psoriatic arthritis
Antibody, autoimmune, monoclonal antibody, psoriatic arthritis, IL-17A/IL-17F inhibitor, biologic therapy - Read more

Relay Therapeutics’ (zovegalisib) achieves 60% response rate in Ph2 trial targeting PIK3Ca-related overgrowth spectrum vascular anomalies
Small molecule, rare disease, PI3K inhibitor, vascular malformations, PIK3CA-related overgrowth spectrum - Read more

Wave Life Sciences' WVE-006 (wve-006) Ph1/Ph2 data support monthly dosing for alpha-1 antitrypsin deficiency via SERPINA1 RNA editing
RNA therapy, metabolic, antisense oligonucleotide, alpha-1 antitrypsin deficiency, SERPINA1, GalNAc-conjugated - Read more

Oorja Bio launches with $30M Series A and FDA-cleared IPF therapy ORJ-001, targeting fibrotic and cardiopulmonary diseases
Clinical-stage, fibrotic disease, peptide therapeutic, cardiopulmonary, idiopathic pulmonary fibrosis - Read more

Lauxera Capital Partners raises €520M ($605M) for health and medtech company expansion
Medtech, digital health, diagnostics, healthcare data, life science tools - Read more

Tarsier Pharma sets terms for $45M IPO, developing steroid-free inflammatory eye disease therapies
Ocular disease, small molecule, autoimmune, clinical-stage - Read more

Toregem BioPharma raises $5.3M Pre-Series C for phase II trials of tooth regeneration antibody
Antibody, rare disease, clinical-stage, tooth agenesis - Read more

Violet Therapeutics raises $4.75M Seed extension to advance EphB3 small molecule program
Neurological, small molecule, preclinical, platform technology, neuroinflammation - Read more

Blank Bio raises $7.2M seed financing, advancing RNA foundation models for precision oncology
AI/ML platform, oncology, RNA, biomarker discovery, diagnostics, precision medicine - Read more

Century Health raises $5M seed round, scaling AI-powered clinical data abstraction platform
AI/ML platform, real-world evidence, data analytics, clinical-stage - Read more

Forlong Biotechnology raises $17.5M Series Pre-B to advance IL-15 and IL-18 pipeline
Oncology, cytokine therapy, bispecific antibody, clinical-stage, immuno-oncology - Read more

Mentari Therapeutics goes public via reverse merger with InMed Pharmaceuticals, raising $290M for migraine pipeline
Monoclonal antibody, neurological, major transaction, financial - Read more

FDA report finds no definitive child deaths caused by COVID-19 vaccines, contradicting Prasad's earlier claims
mRNA vaccine, infectious disease, safety, revenue impact - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Phesi report warns AI is scaling clinical trial flaws by ignoring patient data connections
Oncology, AI/technology, operational, financial - Read more

Takeda faces potential $2.5B damages after jury finds anticompetitive Amitiza generic delay deal
Small molecule, gastrointestinal, competitive, financial - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here